Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome. - Full Text View

Sponsor:	Oregon Health and Science University
Information provided by:	Oregon Health and Science University
ClinicalTrials.gov Identifier:	NCT00720616

Purpose

Study hypothesis:

Low dose growth hormone (GH), through its generation of free 'bioavailable' insulin-like growth factor (IGF)-I, can improve insulin sensitivity and the metabolic profile of subjects with metabolic syndrome.

Study aims:

The purpose of this study is to determine the mechanism of how low dose GH treatment affects the body's sensitivity to insulin actions and whether this low GH dose can affect the body's handling of steroid hormone levels (cortisol clearance) and fat deposition in subjects with metabolic syndrome.

Study design: Subjects that satisfy the criteria of metabolic syndrome (central obesity, treated or untreated high blood pressure, high cholesterol and impaired fasting glucose levels) will be invited to participate in this study. The subjects will be assessed at the initial visit to ascertain their suitability before further participation in the study. If eligible, an equal number of men and women will be randomized (like a flip of a coin) to receive either daily low dose GH or placebo injections first for 12 weeks, before exchanging over for another 12 weeks of treatment after a 4-week washout period. Before, during and after treatment, the subjects will be assessed at frequently with blood tests, scans and fat biopsies. During the study, the subjects will be studied 4 times at the Oregon Clinical and Translational Research Institute (OCTRI). At the first, second and final visit, testing will include scans to measure the amount of whole body fat and fat in the stomach area, muscle, and liver; blood tests to measure levels of cortisol, and fat tissue (taken from a biopsy) analysis to measure the density of insulin-like growth factor-I (a hormone stimulated by growth hormone in the body) in fat; whereas blood tests to examine how well insulin works in the body (insulin sensitivity) will be collected at all visits of the study.

Condition	Intervention
Metabolic Syndrome	Drug: Norditropin

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Effects of a Fixed Low Dose Growth Hormone Therapy on Insulin Sensitivity, Metabolic Profile, Adipocyte IGF-I and Insulin Signalling, Intramyocellular and Intrahepatic Lipids, and Cortisol Metabolism in Subjects With Metabolic Syndrome.

Resource links provided by NLM:

MedlinePlus related topics: Diabetes Medicines Metabolic Syndrome

Drug Information available for: Insulin Insulin beef Somatropin Somatotropin

U.S. FDA Resources

Further study details as provided by Oregon Health and Science University:

Primary Outcome Measures:

Changes in insulin sensitivity, and adipocyte IGF-I and insulin receptor signaling. [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Changes in body composition, cortisol production rates, and muscle and liver intramyocellular content. [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	12
Study Start Date:	October 2008
Estimated Study Completion Date:	December 2010
Estimated Primary Completion Date:	October 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 Growth hormone or Placebo 0.1 mg/day self-administrated once a day.	Drug: Norditropin Norditropin 0.1 mg/day self-administered once a day subcutaneously Other Name: Growth hormone, metabolic syndrome, insulin sensitivity

Show Detailed Description

Eligibility

Ages Eligible for Study:	21 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Ability to provide written informed consent and comply with study assessments for the full duration of the study.
Age 21 to 65 years
Body mass index between 25 to 40 kg/m2
Diagnosis of MBS based on the consensus statement by the International Diabetes Federation i.e., central obesity defined by waist circumference in men of ≥ 94 cm and in women of ≥ 80 cm plus two other components from the following: 1) dyslipidemia (triglyceride levels ≥ 150 mg/dl or on therapy and/or HDL in men of < 40 mg/dl and in women of < 50 mg/dl or on therapy); 2) hypertension (blood pressure ≥ 130/85 mmHg or on therapy and 3) hyperglycemia (fasting plasma glucose ≥ 100 mg/dl or on therapy)
Stable weight and diet for at least 6 months prior to study entry
Normal thyroid function
Normal renal and hepatic function
Able to self administer GH/Placebo injections

Exclusion Criteria:

Inability to comply with study requirements
Body mass index < 30 kg/m2 and > 40 kg/m2 (patients with body mass index > 40 kg/m2 are excluded because they will not fit into the MRS scanner)
Untreated hypothyroidism or hyperthyroidism
Anemia from any cause
Known diabetes mellitus
Patients with an increased risk of venous thrombosis or previous history of recurrent venous thrombosis
Patient on any insulin-sensitizers (e.g., Metformin, Rosiglitazone, Pioglitazone) within 30 days of screening assessment
Patient on any anti-androgens (e.g., Spironolactone, Cyproterone acetate, Flutamide, Finasteride) within 30 days of screening assessment
Patient with other concurrent illnesses
Pregnant (positive pregnancy test) prior enrollment in the study or planning to conceive whilst participating in the study
Emotional/social instability likely to prejudice study completion
Previous history of known malignancy
Recurrent or severe unexplained hypoglycemia
Known or suspected drug/alcohol abuse
Patient with any metals in the body
Any other condition/s that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
Participation in another simultaneous medical investigation or trial

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00720616

Contacts

Contact: Kevin C. Yuen, MRCP(UK), MD	503 494 0175	yuenk@ohsu.edu
Contact: David M. Cook, MD	503 494 3713	cookd@ohsu.edu

Locations

United States, Oregon
Oregon Health and Science University	Not yet recruiting
Portland, Oregon, United States, 97239
Contact: Kevin C. Yuen, MRCP(UK), MD 503-494-0175 yuenk@ohsu.edu
Contact: David M. Cook, MD 503 494 3713 cookd@ohsu.edu
Principal Investigator: Kevin C. Yuen, MRCP(UK), MD

Sponsors and Collaborators

Oregon Health and Science University

Investigators

Principal Investigator:

Kevin C. Yuen, MRCP(UK), MD

Oregon Health and Science University

More Information

Additional Information:

American Endocrine Society This link exits the ClinicalTrials.gov site

Publications:

Yuen K, Wareham N, Frystyk J, Hennings S, Mitchell J, Fryklund L, Dunger D. Short-term low-dose growth hormone administration in subjects with impaired glucose tolerance and the metabolic syndrome: effects on beta-cell function and post-load glucose tolerance. Eur J Endocrinol. 2004 Jul;151(1):39-45.

Responsible Party:	Kevin Yuen, MD, Oregon Health and Science University
ClinicalTrials.gov Identifier:	NCT00720616 History of Changes
Other Study ID Numbers:	IRB4481
Study First Received:	July 21, 2008
Last Updated:	July 22, 2008
Health Authority:	United States: Institutional Review Board

Keywords provided by Oregon Health and Science University:

Growth hormone
Metabolic syndrome
Insulin sensitivity

Additional relevant MeSH terms:

Metabolic Syndrome X
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Hormones

Insulin
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Hypoglycemic Agents

ClinicalTrials.gov processed this record on February 09, 2012